Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis

Cancer Research

Volumn 69, Issue 17, 2009, Pages 6969-6977

  Gilmartin, Aidan G ^a   Bleam, Maureen R ^a   Richter, Mark C ^a   Erskine, Symon G ^a   Kruger, Ryan G ^a   Madden, Lenore ^a   Hassler, Daniel F ^a   Smith, Gary K ^a   Gontarek, Richard R ^a   Courtney, Mary P ^a   Sutton, David ^a   Diamond, Melody A ^a   Jackson, Jeffrey R ^a   Laquerre, Sylvie G ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; GSK 461364 A; HISTONE H3; POLO LIKE KINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL ACTIVATION; CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL FATE; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROMETAPHASE; TUMOR CELL; TUMOR REGRESSION; TUMOR XENOGRAFT;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE; HUMANS; MICE; MICE, NUDE; MITOSIS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; THIOPHENES; TUMOR MARKERS, BIOLOGICAL;

EID: 70149099357     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0945     Document Type: Article

References (46)

1. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? [Review]. Nat Rev Cancer 2007;7:107-117
2. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Hunter T, Osada H. M-phase kinases induce phosphodependent ubiquitination of somatic Wee1by SCF β-TrCP. Proc Natl Acad Sci U S A 2004;101:4419-4424 (Pubitemid 38437427)
3. Toyoshima-Morimoti F, Taniguchi E, Shinya N, Iwamatsu A, Nishida E. Polo-like kinase 1phosphor - ylates cyclin B1and targets it to the nucleus during prophase (vol 410, pg 215, 2001). Nature 2001;410:847-+. (Pubitemid 32303788)
4. Toyoshima-Morimoto F, Taniguchi E, Nishida E, Authors FN, Taniguchi E, Nishida E. Plk1promot es nuclear translocation of human Cdc25C during prophase. EMBO Rep 2002;3:341-348 (Pubitemid 34467604)
5. Jackman M, Lindon C, Nigg EA, et al. Active cyclin B1-1 first appears on centrosomes in prophase. Nat Cell Biol 2003;5:143-148 (Pubitemid 36204196)
6. Lane HA, Nigg EA, Authors FN, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1(Plk1 ) in the functional maturation of mitotic centrosomes. J Cell Biol 1996;135:1701-1713
7. Losada A, Hirano M, Hirano T, Authors FN, Hirano M, Hirano T. Cohesin release is required for sister chromatid resolution, but not for condensin-mediated compaction, at the onset of mitosis. Genes Dev 2002;16:3004-3016 (Pubitemid 35424189)
8. Sumara I, Vorlaufer E, Stukenberg PT, et al. The dissociation of cohesin from chromosomes in prophase is regulated by polo-like kinase. Mol Cell 2002;9:515-525 (Pubitemid 34273783)
9. Gimenez-Abian JF, Sumara I, Hirota T, et al. Regulation of sister chromatid cohesion between chromosome arms. Curr Biol 2004;14:1187-1193 (Pubitemid 38893982)
10. Golan A, Yudkovsky Y, Hershko A. The cyclin-ubiquitin ligase activity of cyclosome/APC is jointly activated by protein kinases Cdk1-cyclin B and Plk. J Biol Chem 2002;277:15552-15557 (Pubitemid 34967823)
11. Kraft C, Herzog F, Gieffers C, et al. Mitotic regulation of the human anaphase-promoting complex by phosphorylation. EMBO J 2003;22:6598-6609 (Pubitemid 38009606)
12. Moshe Y, Boulaire J, Pagano M, et al. Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc Natl Acad Sci U S A 2004;101:7937-7942 (Pubitemid 38698032)
13. Hansen DV, Loktev AV, Ban KH, Jackson PK. Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCF β TrCP-dependent destruction of the APC inhibitor Emi1. Mol Biol Cell 2004;15:5623-5634
14. van Vugt MA, van de Weerdt BC, Vader G, et al. Pololike kinase-1is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem 2004;279:36841-36854 (Pubitemid 39129033)
15. Sumara I, Gimenez-Abian JF, Gerlich D, et al. Roles of polo-like kinase 1in the assembly of functional mitotic spindles. Curr Biol 2004;14:1712-1722 (Pubitemid 39301160)
16. Ahonen LJ, Kallio MJ, Daum JR, et al. Polo-like kinase 1creates the tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-checkpoint proteins at kinetochores. Curr Biol 2005;15:1078-1089
17. Wong OK, Fang G, Authors FN, Fang G. Plx1is the 3F3/2 kinase responsible for targeting spindle checkpoint proteins to kinetochores. J Cell Biol 2005;170:709-719 (Pubitemid 41242104)
18. Kang YH, Park JE, Yu LR, et al. Self-regulated Plk1 recruitment to kinetochores by the Plk1-1 interaction is critical for proper chromosome segregation.[see comment]. Mol Cell 2006;24:409-422
19. Smith MR, Wilson ML, Hamanaka R, et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997;234:397-405. (Pubitemid 27243915)
20. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005;24:287-291
21. McInnes C, Mezna M, Fischer PM, Authors FN, Mezna M, Fischer PM. Progress in the discovery of polo-like kinase inhibitors. [Review] [161 refs]. Curr Top Med Chem 2005;5:181-197
22. McInnes C, Mazumdar A, Mezna M, et al. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol 2006;2:608-617 (Pubitemid 44610345)
23. Peters U, Cherian J, Kim JH, et al. Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat Chem Biol 2006;2:618-626 (Pubitemid 44610346)
24. Hofheinz R, Hochhaus A, Al-Batran S, et al. A phase I repeated dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumours. J Clin Oncol (Meeting Abstracts) 2006;24:2038.
25. Munzert G, Steinbild S, Frost A, et al. A phase I study of two administration schedules of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2006;24:3069.
26. Ohnuma T, Cho SY, Roboz J, et al. Phase I study of ON 01910.Na by 3-day continuous infusion (CI) in patients (pts) with advanced cancer. J Clin Oncol (Meeting Abstracts) 2006;24:13137.
27. Donehower RC, Jimeno A, Li J, et al. Phase I study of ON-01910.Na, a novel cell cycle inhibitor in adult patients with solid tumors. J Clin Oncol (Meeting Abstracts) 2006;24:13026.
28. Steegmaier M, Hoffmann M, Baum A, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo . Curr Biol 2007;17:316-322 (Pubitemid 46241881)
29. Lenart P, Petronczki M, Steegmaier M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007;17:304-315 (Pubitemid 46251642)
30. Yung-Chi C, Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108
31. Lansing TJ, McConnell RT, Duckett DR, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther 2007;6:450-459
32. Emmitte KA, Andrews CW, Badiang JG, et al. Discovery of thiophene inhibitors of polo-like kinase. Bioorg Med Chem Lett 2009;19:1018-1021
33. Spankuch-Schmitt B, Wolf G, Solbach C, et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002;21:3162-3171 (Pubitemid 34548087)
34. Cogswell JP, Brown CE, Bisi JE, et al. Dominant-negative polo-like kinase 1induces mitotic catastrophe independent of cdc25C function. Cell Growth Diff 2000;11:615-623
35. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, et al. Effect of RNA silencing of polo-like kinase-1(PLK1 ) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002;94:1863-1877.
36. Nousiainen M, Silljé HHW, Sauer G, Nigg EA, Körner R. Phosphoproteome analysis of the human mitotic spindle. 2006;103:5391-5396
37. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008;14:111-122
38. Tao W, South VJ, Zhang Y, et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005;8:49-59. (Pubitemid 40991814)
39. Rieder CL, Maiato H. Stuck in Division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004;7:637-651 (Pubitemid 39462685)
40. Weaver BAA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005;8:7-12.
41. Lanni JS, Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 1998;18:1055-1064 (Pubitemid 28063440)
42. 1 tetraploidy checkpoint and the suppression of tumorigenesis. J Cell Biochem 2003;88:673-683
43. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006;66:7668-7677 (Pubitemid 44289225)
44. Vijapurkar U, Wang W, Herbst R. Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways. Cancer Res 2007;67:237-245 (Pubitemid 46142780)
45. Tao W, South VJ, Diehl RE, et al. An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. Mol Cell Biol 2007;27:689-698 (Pubitemid 46080134)
46. Shoemaker AR, Oleksijew A, Bauch J, et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 2006;66:8731-8739 (Pubitemid 44449190)